Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $58.42 Consensus Price Target from Brokerages

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month […]

Related Keywords

Robertw Baird ,Marc Wilson ,Dana Pizzuti ,News Ratings For Crinetics Pharmaceuticals Daily ,Artal Group ,Janus Henderson Group ,Crinetics Pharmaceuticals Inc ,Cantor Fitzgerald ,Crinetics Pharmaceuticals ,Jennison Associates ,Analyst Recommendations For Crinetics Pharmaceuticals ,Pricet Rowe Associates Inc ,Institutional Investors Weigh In On Crinetics Pharmaceuticals ,Morgan Stanley ,Crinetics Pharmaceuticals Stock Performance ,Securities Exchange Commission ,Nasdaq ,Get Free Report ,Exchange Commission ,Henderson Group ,Pricet Rowe Associates ,Get Free ,Crinetics Pharmaceuticals Daily ,